Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors.
Troise F, Leoni G, Sasso E, Del Sorbo M, Esposito M, Romano G, Allocca S, Froechlich G, Cotugno G, Capone S, Folgori A, Scarselli E, D'Alise AM, Nicosia A. Troise F, et al. Among authors: romano g. Mol Ther Oncol. 2024 Jan 10;32(1):200760. doi: 10.1016/j.omton.2024.200760. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596303 Free PMC article.
VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens' Prediction.
Leoni G, D'Alise AM, Tucci FG, Micarelli E, Garzia I, De Lucia M, Langone F, Nocchi L, Cotugno G, Bartolomeo R, Romano G, Allocca S, Troise F, Nicosia A, Lahm A, Scarselli E. Leoni G, et al. Among authors: romano g. Vaccines (Basel). 2021 Aug 9;9(8):880. doi: 10.3390/vaccines9080880. Vaccines (Basel). 2021. PMID: 34452005 Free PMC article.
Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
Seclì L, Infante L, Nocchi L, De Lucia M, Cotugno G, Leoni G, Micarelli E, Garzia I, Avalle L, Sdruscia G, Troise F, Allocca S, Romano G, Scarselli E, D'Alise AM. Seclì L, et al. Among authors: romano g. J Immunother Cancer. 2023 Apr;11(4):e006718. doi: 10.1136/jitc-2023-006718. J Immunother Cancer. 2023. PMID: 37117006 Free PMC article.
Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer.
D'Alise AM, Nocchi L, Garzia I, Seclì L, Infante L, Troise F, Cotugno G, Allocca S, Romano G, Lahm A, Leoni G, Sasso E, Scarselli E, Nicosia A. D'Alise AM, et al. Among authors: romano g. Front Immunol. 2023 Apr 26;14:1156714. doi: 10.3389/fimmu.2023.1156714. eCollection 2023. Front Immunol. 2023. PMID: 37180141 Free PMC article.
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine.
Garzia I, Nocchi L, Avalle L, Troise F, Leoni G, Seclì L, Antonucci L, Cotugno G, Allocca S, Romano G, Conti L, Caiazza C, Mallardo M, Poli V, Scarselli E, D'Alise AM. Garzia I, et al. Among authors: romano g. Cancer Immunol Res. 2024 Apr 2;12(4):440-452. doi: 10.1158/2326-6066.CIR-23-0609. Cancer Immunol Res. 2024. PMID: 38331413 Free PMC article.
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.
Bartolomeo R, Troise F, Allocca S, Sdruscia G, Vitale R, Bignone V, Petrone AM, Romano G, D'Alise AM, Ruzza V, Garzia I, Leoni G, Merone R, Lanzaro F, Colloca S, Siani L, Scarselli E, Cotugno G. Bartolomeo R, et al. Among authors: romano g. Vaccines (Basel). 2024 Mar 19;12(3):325. doi: 10.3390/vaccines12030325. Vaccines (Basel). 2024. PMID: 38543959 Free PMC article.
Molecular characterization of emerging Echovirus 11 (E11) shed light on the recombinant origin of a variant associated with severe hepatitis in neonates.
Piralla A, Giardina F, Ferrari G, Gaiarsa S, Romano G, Pellegrinelli L, Galli C, Seiti A, Binda S, Pitrolo AMG, Genoni A, Ferrante FD, Novazzi F, Mancini N, Rovida F, Pariani E, Baldanti F. Piralla A, et al. Among authors: romano g. J Med Virol. 2024 May;96(5):e29658. doi: 10.1002/jmv.29658. J Med Virol. 2024. PMID: 38727043
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab.
Signoriello E, Signori A, Lus G, Romano G, Marfia GA, Landi D, Napoli F, D' Amico E, Zanghí A, Di Filippo PS, Caliendo D, Carotenuto A, Spiezia AL, Fantozzi R, Centonze D, Lucchini M, Mirabella M, Cocco E, Frau J, Maniscalco GT, Di Battista ME, Foschi M, Surcinelli A, Bonavita S, Abbadessa G, Pasquali L, Di Gregorio M, Ferrò MT, Sormani MP, Schiavetti I; ON focus study group. Signoriello E, et al. Among authors: romano g. Mult Scler Relat Disord. 2024 Apr 6;87:105594. doi: 10.1016/j.msard.2024.105594. Online ahead of print. Mult Scler Relat Disord. 2024. PMID: 38718748 Free article.
1,312 results